In build
Early detection and support for neurodivergent minds.
A HIPAA-compliant platform pairing patients with therapists around standardised screening, daily wellness tracking and explicit consent control.
Visit the product
Neurodivergence is usually caught late, by accident, and often not at all. The screening that exists is fragmented across instruments and rarely reaches the people who need it. NeuroKind is the detection and support layer underneath that gap.
Patients complete standardised screening, PHQ-9, GAD-7 and AQ-10, then track mood, energy, social connection and stressors day to day. Therapists see progress, trends and crisis signals in one place rather than reconstructing them from memory at the start of a session.
Consent is the architectural decision, not a settings page. Data reaches a clinician only when the patient explicitly says so, which is what separates this from a workplace wellness product wearing clinical language.
What it does
- Standardised screening: PHQ-9, GAD-7, AQ-10
- Daily tracking across mood, energy and stressors
- Crisis signals surfaced to the treating clinician
- Granular, patient-held consent